Drug Profile
LY 3053102
Alternative Names: LY-3053102Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Dec 2015 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Singapore (SC)
- 23 Dec 2015 Discontinued - Phase-I/II for Type-2 diabetes mellitus in USA (SC)
- 24 Feb 2015 Eli Lilly terminates a phase I/II trial for Type-2 diabetes mellitus in USA (NCT02020616)